Detailed findings, based on tests involving a closely related line of mice that helped drive early-stage research for MEK inhibitors, were published, in the journal Science Advances.

“These findings provide compelling preclinical evidence for KRAS inhibition as a novel treatment strategy for NF1-associated neurofibromas,” Ratner says.

What is NF1?

Individuals with neurofibromatosis type 1 develop Schwann cell tumors called neurofibromas that arise within peripheral nerves. NF1 affects about one in every 2,500 to 3,000 newborns. In the United States, about 100,000 to 120,000 people of all ages live with an NF diagnosis.